The European Medicines Agency (EMA) confirmed it will turn an EU-level clinical trial advice pilot into a permanent option for sponsors. That change means companies can continue seeking harmonized regulatory input through the mechanism beyond the pilot window, potentially smoothing planning for multi-country development. For biotech teams designing trials across the EU, the update reduces uncertainty around guidance access timing and may help standardize submission strategies earlier in development.